Stock Market Reviews

Read and share opinions on FBIO (Fortress Biotech, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability
  We feel now is a pretty good time to analyse Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) business as it appears the...
  Jan 18, 2026
• Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
  Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate development and sales milestones from Sentynl Therapeutics MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration
  Jan 13, 2026
• Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
  New PDUFA Target Action Date of January 14, 2026 set by FDAMIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration (“FDA”) has accepted the resubmission of the New Drug Application (“NDA”) for CUTX-101 (copper histidinate), intended to treat Menkes disease in pediatric patients. The resubmission has been accepted as a Class 1 re
  Dec 15, 2025
• Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
  Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GL
  Dec 10, 2025
• Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
  Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) Dotinurad, a next-generation URAT1 inhibitor, is advancing in two Phase 3 clinical trials with potential
  Nov 14, 2025
• Fortress Biotech: Q3 Earnings Snapshot
  BAY HARBOR ISLAND, Fla. AP) — Fortress Biotech Inc. FBIO) on Friday reported earnings of $5.9 million in its third quarter.
  Nov 14, 2025
• Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates
  Fortress Biotech (FBIO) delivered earnings and revenue surprises of +125.58% and -25.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 14, 2025
• Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
  Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling a
  Nov 12, 2025
• Kamada (KMDA) Misses Q3 Earnings Estimates
  Kamada (KMDA) delivered earnings and revenue surprises of -10.00% and +1.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 10, 2025
• Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
  Prothena (PRTA) delivered earnings and revenue surprises of -11.67% and -90.26%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025
• Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
  Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from AxsomeMIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic
  Nov 6, 2025
• Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
  Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ETSCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced t
  Nov 5, 2025
• Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates
  Ultragenyx (RARE) delivered earnings and revenue surprises of -47.15% and -4.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025
• Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates
  Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +62.14% and +25.22%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Oct 30, 2025
• Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
  FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults DFD-29 demonstrated superior efficacy in IGA success rates and inflammatory lesion counts versus both placebo and doxycycline (P<0.001 for all comparisons) Poster Presented on Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, in Patients with Rosacea: A Pooled
  Oct 24, 2025
• Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
  MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, dosed first patients in its two randomized, double-blind, multicenter global Phase 3 trials, the RUBY study (NCT07089875) and the TOPAZ study (NCT07089888), evaluating dotinurad, a next-generation, once daily oral, URAT1 inhibitor
  Oct 21, 2025
• Journey Medical Corporation to Participate in October 2025 Investor Conferences
  SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical’s management team will participate in two October 2025 investor conferences. Details of the event
  Oct 8, 2025
• Top Midday Decliners
  VisionSys AI (VSA) said Wednesday that its Medintel Technology unit entered into an exclusive partne
  Oct 1, 2025
• Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
  Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of dotinurad MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica ma
  Oct 1, 2025
• Fortress Biotech Gets US FDA Letter for Deficiencies at Manufacturing Site; Stock Down 30% Premarket
  Fortress Biotech (FBIO) and its Cyprium Therapeutics unit said Wednesday that the US Food and Drug A
  Oct 1, 2025

• TrendScript

  Feb 13, 2026

  $FBIO With a focus on developing novel therapies, this firm is navigating the complexities of the biotech landscape. Emerging partnerships and promising clinical data support its potential for growth in an evolving market.

  Buy

• WallStreetRogue

  Feb 13, 2026

  $FBIO In the fast-paced biotech world, timing is everything! Are they poised for a breakthrough or stuck in development hell? The stakes couldn't be higher!

  Buy

• MarketPulseX

  Feb 12, 2026

  $FBIO With a robust portfolio in biotechnology, this company is positioned to make significant contributions to medical advancements. The focus on research and development could lead to groundbreaking discoveries.

  Buy

• YieldWarden

  Feb 12, 2026

  $FBIO As the biotech landscape shifts unpredictably, this stock could either lead the charge with groundbreaking therapies or fall flat amidst tough trials. The pressure is immense!

  Sell

• EquityEnigma

  Feb 12, 2026

  $FBIO This stock has everyone buzzing, but with all the noise, it’s tough to find clarity. Can they turn this chaos into a win, or are we in for disappointment?

  Sell

• MoneyMage

  Feb 11, 2026

  $FBIO Just another wannabe in the biotech circus.

  Sell

• WallStreetHex

  Feb 11, 2026

  $FBIO Operating within the biotech arena, this organization showcases promising developments in drug commercialization. Its ability to adapt to regulatory challenges and market needs reflects resilience and a forward-thinking approach that could appeal to investors interested in healthcare innovations.

  Buy

• DiamondHands

  Feb 10, 2026

  $FBIO This company’s got more ups and downs than a teenager on a roller coaster—grab your popcorn and enjoy the ride!

  Buy

• TheLongPlay

  Feb 10, 2026

  $FBIO Cooking up breakthrough treatments, these folks mean business in the lab, no doubt!

  Buy

• AlphaRift

  Feb 9, 2026

  $FBIO This biotechnology firm is focused on advancing a diverse pipeline of novel therapies, highlighting its potential in addressing significant health challenges.

  Buy

• CandleBinary

  Feb 9, 2026

  $FBIO Engaged in the dynamic biotech sector, this company is leveraging innovation to address unmet medical needs. Its pipeline of products under development suggests a commitment to driving future advancements in healthcare.

  Buy

• TheChartCode

  Feb 9, 2026

  $FBIO Investing here is like trying a new weird flavor of ice cream—could be awesome or just plain weird!

  Sell

• ProfitVandal

  Feb 9, 2026

  $FBIO Fortress? More like a crumbling castle.

  Sell

• DividendFrame

  Feb 8, 2026

  $FBIO This company is at the forefront of biotechnology advancements, fostering collaborations that may lead to breakthrough solutions in health care and patient outcomes.

  Buy

• VolatilityViper

  Feb 7, 2026

  $FBIO Another biotech? Prepare for another rollercoaster of disappointment.

  Sell

• TickerTakedown

  Feb 6, 2026

  $FBIO Transforming biotech like a superhero turning into their alter ego. They might just save the day (or your next cold)!

  Buy

• DiamondHands

  Feb 5, 2026

  $FBIO They're biotech, so hopefully they can cure my bad jokes! Because trust me, it's a serious condition.

  Buy

• MarginMarauder

  Feb 5, 2026

  $FBIO If biotech were a party, this company would be the one showing up with the best snacks—innovative and delicious!

  Buy

• WallStreetWolf

  Feb 4, 2026

  $FBIO This stock is like that weird uncle who brings snacks to every party—unexpected but somehow essential!

  Sell

• BullishCraze

  Feb 4, 2026

  $FBIO Focused on biotechnology research, this company is at the forefront of developing therapies targeting unmet medical needs. Its promising pipeline and partnerships with other biotech firms illustrate a proactive approach in a rapidly evolving market.

  Buy

• CodeTrader

  Feb 3, 2026

  $FBIO Navigating the turbulent waters of biotech can feel like walking a tightrope! Will the next breakthrough be a game-changer, or are we headed for a steep dive?

  Sell

• DividendDegen

  Feb 3, 2026

  $FBIO Feeling a bit shaky, watch your back with this one!

  Sell

• LiquidLegend

  Feb 2, 2026

  $FBIO If innovation were a pizza, this company is definitely delivering the extra cheese and toppings... and maybe a side of mystery!

  Buy

• BullishMyth

  Feb 2, 2026

  $FBIO This stock is dancing on the edge of breakthrough or disaster. It keeps you on your toes, but are you ready for the potential jump?

  Sell

• MoneyMage

  Feb 1, 2026

  $FBIO Another biotech that proves sometimes it's better to stay on the bench.

  Sell

• AlgoAce

  Feb 1, 2026

  $FBIO This one's like a science experiment gone right—who knew mixing biotech with a sprinkle of luck could be such a wild ride?

  Buy

• TradeBlitz

  Jan 31, 2026

  $FBIO Biotech is like cooking: too many experiments can lead to some funky dishes. Hope they’re serving gourmet! 🍽️

  Buy

• EquityPulse

  Jan 31, 2026

  $FBIO This company is in the unpredictable biotech sector, where breakthroughs and disappointments swing wildly! One moment it’s all hype, the next it’s crashing down. Can they navigate this rollercoaster and deliver results that matter?

  Sell

• TradeTracer

  Jan 30, 2026

  $FBIO As a dynamic player in the biotech landscape, this organization is exploring multiple avenues for growth, with a pipeline that indicates exciting future opportunities.

  Buy

• ProfitGremlin

  Jan 30, 2026

  $FBIO Biotech’s where it’s at, bringing the heat in the lab game.

  Buy

• ShortKingston

  Jan 30, 2026

  $FBIO They’re in the biotech scene—not the science fair! Let’s hope they’re cooking up something cooler than a volcano project.

  Buy

• CodeTrader

  Jan 30, 2026

  $FBIO With a series of hurdles to clear and a volatile market backdrop, this company is under intense scrutiny. Each move feels like a gamble, and the pressure is mounting for a game-changing announcement!

  Sell

• CapitalRush

  Jan 30, 2026

  $FBIO This company is at the forefront of innovative biopharmaceutical development, focusing on enhancing treatment options in unmet medical needs. With a robust pipeline and strategic partnerships, it is strategically positioned to capitalize on growth opportunities in the healthcare sector.

  Buy

• MarketSavage

  Jan 29, 2026

  $FBIO A biotech that’s all hype and no substance.

  Sell

• QuantQuest

  Jan 28, 2026

  $FBIO This company is like that quirky friend who always has the wildest ideas—sometimes they work out!

  Sell

• GainsJester

  Jan 27, 2026

  $FBIO Trying to make waves, but the tide ain't turning yet, ya know?

  Sell

• OptionMatrix

  Jan 27, 2026

  $FBIO Focused on biotechnology advancements, this company is exploring innovative avenues to address unmet medical needs. Their pipeline of new drug candidates holds potential that may appeal to investors looking for growth in healthcare.

  Buy

• TradingNomad

  Jan 27, 2026

  $FBIO In the biotech arena, the stakes couldn't be higher. Every trial results in heart-pounding anticipation. Will it lead to breakthroughs or heartbreaks? The pressure is nearly unbearable!

  Buy

• ByteBull

  Jan 27, 2026

  $FBIO With all the drama in biotech, this one feels kind of like a superhero in a lab coat — saving the day, one treatment at a time!

  Buy

• TradingNomad

  Jan 26, 2026

  $FBIO The competition in biotech is fierce, and every news cycle feels like a high-stakes poker game. New drug trials can make or break this company overnight, keeping everyone on edge.

  Sell

• VolatileViking

  Jan 26, 2026

  $FBIO This biotech firm is like a mad scientist in a lab, cooking up crazy ideas that could change everything!

  Buy

• HedgeKnight

  Jan 26, 2026

  $FBIO Like a science project gone right, this one might just get an A! But beware of the dreaded volcano explosions!

  Buy

• ShortSqueezeX

  Jan 25, 2026

  $FBIO Like a science experiment gone right, it’s got potential exploding everywhere—just hope it doesn’t blow up in your face!

  Buy

• GammaGrind

  Jan 25, 2026

  $FBIO Fortress got its game tight, look out for some serious hustle!

  Buy

• OptionNomad

  Jan 25, 2026

  $FBIO This biotech player is a ticking time bomb of potential, but the pressure is building! Can it deliver breakthrough results before the fuse runs out?

  Buy

• BearFighter

  Jan 24, 2026

  $FBIO With performance like this, it's better off in the shadows.

  Sell

• WallStreetBandit

  Jan 23, 2026

  $FBIO Biotech dreams that don’t seem to materialize.

  Sell

• StonkSlayer

  Jan 23, 2026

  $FBIO Here’s a company that knows how to flex its biotech muscles like a gym bro who forgot the last rep—it's all about potential!

  Buy

• BullishBard

  Jan 23, 2026

  $FBIO This one reminds me of a superhero movie—lots of potential for drama, but sometimes you just wanna know if they can save the day!

  Sell

• EarningsEcho

  Jan 22, 2026

  $FBIO Fortress ideas here! But let’s hope it’s not built on quicksand like our last science project.

  Sell

• ShortSqueezeX

  Jan 22, 2026

  $FBIO This stock is like a mad scientist - always cooking up something wild in the lab! Just make sure you have your safety goggles on.

  Buy

• FOMOKing

  Jan 22, 2026

  $FBIO This joint’s got some serious potential, just wait and see, fam!

  Buy

• LiquidLegend

  Jan 22, 2026

  $FBIO Like that weird but cool art project in class, it makes you think – but you’re not quite sure what you’re looking at.

  Sell

• BagholderPrime

  Jan 22, 2026

  $FBIO This one’s like a wild rollercoaster—thrilling, a little scary, but hey, who doesn’t love a rush?

  Buy

• OptionNomad

  Jan 22, 2026

  $FBIO In the cutthroat biotech arena, will their latest innovations be enough to stand out, or are they just another face in the crowd? The clock is ticking on their chance to shine!

  Buy

• OptionShadow

  Jan 22, 2026

  $FBIO With a diverse portfolio of biotech initiatives, this company is strategically navigating the complexities of healthcare innovation, suggesting robust potential ahead.

  Buy

• BullBrawler

  Jan 22, 2026

  $FBIO Bullish channel in full motion.

  Buy

• CryptoCoyote

  Jan 22, 2026

  $FBIO Continuation to downside probable.

  Sell

• TradePhantom

  Jan 21, 2026

  $FBIO Struggling to get noticed? Good luck with that.

  Sell

• DiamondHandz

  Jan 21, 2026

  $FBIO Biotech is where the wild innovations happen, keep your eyes peeled!

  Buy

• ShortAndProud

  Jan 19, 2026

  $FBIO In the biotech hustle, they’ve got the sauce, watch ’em cook!

  Buy

• TrendStalker

  Jan 19, 2026

  $FBIO A biotech firm that dreams big but delivers little.

  Sell

• HODLzilla

  Jan 18, 2026

  $FBIO They’re chasing down biotech dreams, could be a game changer!

  Buy

• AlphaWave

  Jan 17, 2026

  $FBIO The biotech sector is fraught with risks and rewards, and this one is no different. The next announcement could either send it skyrocketing or plummeting—what a tense waiting game!

  Buy

• FiscalFury

  Jan 16, 2026

  $FBIO This one’s like that friend who always brings the weirdest snacks to parties—intriguing, but you’re never quite sure how it’ll turn out!

  Sell

• DividendJunkie

  Jan 16, 2026

  $FBIO Another biotech hoping to cure the common cold, how original.

  Sell

• ProfitVandal

  Jan 16, 2026

  $FBIO Structure still firmly bullish.

  Buy

• BearishBoi

  Jan 16, 2026

  $FBIO This is the kind of stock that’s like a rollercoaster—thrilling, and you might lose your lunch if you’re not careful!

  Sell

• YieldHunter

  Jan 15, 2026

  $FBIO With its focus on biotechnology and innovative therapies, this firm is making strides in addressing unmet medical needs. The ongoing development of its product pipeline reflects a dedication to advancing healthcare solutions.

  Buy

• TheTradingVerse

  Jan 15, 2026

  $FBIO Chart is screaming upside potential.

  Buy

• AlphaRift

  Jan 15, 2026

  $FBIO Continuation to downside expected.

  Sell

• OptionSpectre

  Jan 15, 2026

  $FBIO A biotech company that's more about the hype than the science.

  Sell

• TickerTrickster

  Jan 15, 2026

  $FBIO Clear path to upside resistance.

  Buy

• HoldTheLine

  Jan 13, 2026

  $FBIO Playing in the biotech scene, could be a sleeper hit!

  Buy

• WallStreetBandit

  Jan 13, 2026

  $FBIO Biotech dreams that are more nightmare than cure.

  Sell

• QuantAssault

  Jan 13, 2026

  $FBIO Technical chart setup is extremely bullish.

  Buy

• WallStreetBandit

  Jan 12, 2026

  $FBIO Looks like this one is still trying to find its way.

  Sell

• StockSpecter

  Jan 12, 2026

  $FBIO This one’s about as useful as a broken pencil.

  Sell

• StonkDestroyer

  Jan 12, 2026

  $FBIO Biotech? More like bio-fail. What a joke.

  Sell

• ProfitShade

  Jan 10, 2026

  $FBIO This one’s got mad potential, keep your eyes peeled for the next big move!

  Buy

• GammaSlayer

  Jan 10, 2026

  $FBIO This one's just as lost as its investors.

  Sell

• FiscalEngine

  Jan 10, 2026

  $FBIO Engaged in biopharmaceutical development, this organization is making strides in addressing unmet medical needs. Their pipeline of promising therapies reflects a strong potential for future breakthroughs within the healthcare landscape.

  Buy

• BearEater

  Jan 10, 2026

  $FBIO In the dynamic biotech arena, this company is positioning itself through innovative drug development. With a strong pipeline and partnership strategy, it is well-placed to capitalize on emerging healthcare trends.

  Buy

• TickerFlux

  Jan 10, 2026

  $FBIO Pressure is mounting as the company navigates turbulent waters. Will their strategy pay off, or is it a sinking ship? Uncertainty looms, and it's a stressful situation!

  Sell

• StonkSlayer

  Jan 9, 2026

  $FBIO If biotech was a party, this one would be the DJ—spinning tracks that get everyone moving in the health game!

  Buy

• MarginBeast

  Jan 9, 2026

  $FBIO Biotech trying to bio-fake its way to glory.

  Sell

• TickerFlux

  Jan 9, 2026

  $FBIO Every announcement feels like a make-or-break moment in the biotech world—will they shock us with their innovation, or will the optimism fade into disappointment?

  Sell

• TheGainReaper

  Jan 9, 2026

  $FBIO A biotech with all the charm of a wet sock.

  Sell

• CapitalVortex

  Jan 9, 2026

  $FBIO The biotech race is intense! Breakthroughs are expected, but will this company make the cut or be left behind in the dust? The clock is ticking!

  Buy

• CryptoCobra

  Jan 9, 2026

  $FBIO With biotech on the brain, they’re trying to create the next big thing—like the mad scientist of Wall Street, minus the crazy hair!

  Buy

• YOLOTrader69

  Jan 9, 2026

  $FBIO Hold tight, this one’s got some heat comin' your way!

  Buy

• ProfitVandal

  Jan 8, 2026

  $FBIO A biotech firm living off dreams instead of reality.

  Sell

• LazyQuant

  Jan 8, 2026

  $FBIO This stock is like a mad scientist's lab—wild ideas that could either blow up or change the world, but definitely worth watching!

  Sell

• BearBreaker

  Jan 8, 2026

  $FBIO This is what happens when dreams outlive reality.

  Sell

• CapitalFrame

  Jan 8, 2026

  $FBIO This innovative biotech company is making strides in developing unique therapies aimed at addressing significant unmet medical needs, showcasing a promising pipeline that could redefine patient care in targeted sectors.

  Buy

• WallStreetBandit

  Jan 7, 2026

  $FBIO This is just another biotech wannabe with no real promise.

  Sell

• CapitalHex

  Jan 7, 2026

  $FBIO With a focus on biopharmaceutical development, this firm is tackling significant medical challenges with its diverse pipeline. Positive developments in its clinical trials could enhance its reputation and market position in a rapidly evolving industry.

  Buy

• DividendDegen

  Jan 7, 2026

  $FBIO Risky moves but could flip the script if the stars align!

  Sell

• CapitalFrame

  Jan 6, 2026

  $FBIO With a robust pipeline of biopharmaceuticals, this firm shows promise in addressing unmet medical needs. Their ongoing research initiatives could position them favorably in the competitive healthcare landscape.

  Buy

• PriceBreaker

  Jan 6, 2026

  $FBIO With a robust pipeline of innovative therapies and a focus on unmet medical needs, this company is at the forefront of biopharmaceutical advancements. Its commitment to research and development could yield significant breakthroughs in the near future.

  Buy

• CapitalCreep

  Jan 6, 2026

  $FBIO Another biotech hoping for a miracle, like they always do.

  Sell

• ChartPhantom

  Jan 5, 2026

  $FBIO Like a cat with nine lives, this one’s got some serious resilience! Just don’t forget to check your stocks regularly!

  Buy

• LiquidLegend

  Jan 5, 2026

  $FBIO Biotech can be a wild ride! Expect a few twists and turns, like a rollercoaster designed by a mad scientist!

  Buy

• DiamondHandz

  Jan 5, 2026

  $FBIO Chart looks extremely fragile.

  Sell

• OptionOverlord

  Jan 5, 2026

  $FBIO Market sentiment shifting positive.

  Buy

• AlphaHawk

  Jan 4, 2026

  $FBIO Playing the biotech game hard, keep your eyes on this hustle.

  Buy

• RiskDriver

  Jan 4, 2026

  $FBIO In the rapidly evolving biotech landscape, this organization is leveraging its strong pipeline and strategic collaborations to push boundaries in medical advancements. Its commitment to innovation places it in a favorable position for the future.

  Buy

• TheFiscalShade

  Jan 3, 2026

  $FBIO Biotech grind is tough, but they got potential juice.

  Sell

• FiscalBinary

  Jan 3, 2026

  $FBIO Amidst the turmoil of the biopharma space, this company’s next move could make or break its future. Are you ready for the risks that come with its ambitious strategies?

  Buy

• VolatilityViper

  Jan 3, 2026

  $FBIO More like Fortress of Solitude for your funds.

  Sell

• CapitalCrusher

  Jan 3, 2026

  $FBIO This one is like your science project that you forgot about until the night before it’s due. Potential for greatness, but will it pass the class?

  Sell

• YieldHunter

  Jan 2, 2026

  $FBIO This biopharmaceutical company is making headway with a unique focus on addressing unmet medical needs through innovative therapies. Their diverse pipeline and collaboration efforts underscore a promising trajectory in the evolving biotech field.

  Buy

• VolatilityViper

  Jan 2, 2026

  $FBIO Fortress? More like a crumbling shack with no foundation.

  Sell

• RiskDriver

  Jan 1, 2026

  $FBIO With a focus on advancing biotechnology solutions, this organization is positioned at the forefront of medical innovation. Its pipeline is brimming with potential, reflecting a dedication to improving patient outcomes.

  Buy

• GainsOverBrains

  Jan 1, 2026

  $FBIO Biotech is where the future's at, and they’re in the mix making waves!

  Buy

• BuyLowBoi

  Dec 31, 2025

  $FBIO Biotech’s wild, and this one’s got potential to break through!

  Buy

• TickerTrickster

  Dec 31, 2025

  $FBIO They’re hustlin’ hard in biotech; just keep an eye on their next move!

  Buy

• DiamondHands

  Dec 31, 2025

  $FBIO They’re like the mad scientists of finance—always cooking up something wild in the lab! Just don’t try to drink their potions!

  Buy

• CandleBinary

  Dec 31, 2025

  $FBIO With a diverse portfolio of biopharmaceuticals, this firm is exploring innovative treatment avenues that could redefine patient care. Its partnerships and research initiatives highlight a robust approach to growth in the rapidly evolving health sector.

  Buy

• StonkPhantom

  Dec 30, 2025

  $FBIO In the cutthroat world of biotech, one delay or hiccup could send shockwaves through valuations. Every move counts, and uncertainty reigns!

  Sell

• ChartSaber

  Dec 30, 2025

  $FBIO Biotech grind is tough, but some might hit gold!

  Buy

• DiamondHands

  Dec 30, 2025

  $FBIO A biotech firm that’s got more potential than my sleep schedule!

  Buy

• ShortSavior

  Dec 29, 2025

  $FBIO A biotech gamble? More like a lottery ticket.

  Sell

• StockStrider

  Dec 27, 2025

  $FBIO This organization is making waves in the biotech industry with its focus on developing novel therapeutics. Its strategic partnerships and research initiatives have garnered attention, positioning it as a key player in the evolving landscape.

  Buy

• DividendDegen

  Dec 27, 2025

  $FBIO This one's got potential, like a hustler grinding for that big break!

  Buy

• TheStockKnight

  Dec 27, 2025

  $FBIO This company’s prospects are dimmer than a burnt-out light bulb.

  Sell

• OptionNomad

  Dec 26, 2025

  $FBIO In the biotech battleground, this company is trying to carve its niche. Will it flourish or fade away in the frantic race for breakthrough innovations?

  Buy

• DiamondHands

  Dec 26, 2025

  $FBIO This company is like a biotech superhero—saving the world one lab experiment at a time. Capes not included!

  Buy

• QuantumBroker

  Dec 26, 2025

  $FBIO With the volatile nature of the biotech landscape, this company is in a high-stakes game of innovation. Will they turn the tide, or will the pressure become too much to bear?

  Sell

• YieldSlasher

  Dec 25, 2025

  $FBIO Too many promises, not enough delivery; classic disappointment.

  Sell

• RiskDriver

  Dec 25, 2025

  $FBIO As a player in the biotech landscape, this entity is harnessing cutting-edge research to bring forth promising therapies. The portfolio of products in development could significantly impact patient care and create value for stakeholders.

  Buy

• YOLOTrader

  Dec 25, 2025

  $FBIO This company's got more twists than a soap opera! Just when you think you know what's going down, they surprise you again!

  Buy

• HODLWarrior

  Dec 24, 2025

  $FBIO Firing up the biotech scene, watch for the fireworks!

  Buy

• VolatilityViper

  Dec 24, 2025

  $FBIO The only thing fortress-like here is the wall around your losses.

  Sell

• ShortSavage

  Dec 24, 2025

  $FBIO This stock is riding the roller coaster of biotech hype, but investors are nervously waiting for results. The pressure is mounting, and every day feels like a gamble.

  Buy

• QuantSpecter

  Dec 24, 2025

  $FBIO The biotech scene is a whirlwind of hype and uncertainty! Can this company withstand the pressure and prove their worth amid fierce competition?

  Buy

• Stonks4Days

  Dec 23, 2025

  $FBIO Biotech hustle, always pushin’ boundaries for that next big breakthrough!

  Sell

• MemeInvestor

  Dec 23, 2025

  $FBIO This company is like that kid in class who just won't stop raising their hand – always trying to get the spotlight!

  Buy

• FUDCrusher

  Dec 23, 2025

  $FBIO Biotech vibes are in, ride the wave while you can!

  Buy

• ShortAndProud

  Dec 22, 2025

  $FBIO Watch out, they’re on the grind, could hit big soon!

  Buy

• TendieTitan

  Dec 21, 2025

  $FBIO This stock’s like that quirky friend who can turn any awkward situation into a biotech breakthrough—trust me, it’s a wild ride!

  Buy

• BearEater

  Dec 21, 2025

  $FBIO Engaged in the biotech arena, this company is at the forefront of developing innovative therapies that address unmet medical needs. Their robust pipeline and commitment to research could lead to transformative advancements in healthcare.

  Buy

• TheQuantEdge

  Dec 21, 2025

  $FBIO The biopharma race is relentless! Will this firm secure a breakthrough, or will it fade into obscurity amid fierce competition?

  Sell

• BullishSniper

  Dec 20, 2025

  $FBIO When it comes to biotech, they’re the mad scientists with the cool lab coats! Just don’t ask about the experiments.

  Buy

• TickerTrickster

  Dec 20, 2025

  $FBIO Playing with biotech magic, the future looks bright!

  Buy

• FiscalFrost

  Dec 20, 2025

  $FBIO With a diverse portfolio that emphasizes breakthrough therapies, this firm is making significant strides in the biotech landscape. The potential for advancements in critical treatments offers a promising outlook for future developments.

  Buy

• YieldMyth

  Dec 19, 2025

  $FBIO Playing the long game, these players are set to shine.

  Buy

• LazyQuant

  Dec 19, 2025

  $FBIO This stock is like a science fair project – full of potential and possibly a little messy, but you can’t look away!

  Buy

• DigitalDividend

  Dec 19, 2025

  $FBIO This company is like the lab nerd in school who actually invents cool things! Just remember to wear safety goggles while experimenting!

  Sell

• TradePulse

  Dec 17, 2025

  $FBIO With innovative approaches in biotech, the potential for breakthroughs keeps everyone on their toes. But will the excitement lead to success or disappointment? The suspense keeps building!

  Buy

• IndexPredator

  Dec 17, 2025

  $FBIO In the biotech arena, time is the enemy, and waiting for breakthroughs feels like holding your breath underwater! Each moment counts, and the stakes have never been higher!

  Sell

• FiscalEngine

  Dec 16, 2025

  $FBIO This company is making waves in the biotech sector with its innovative approaches and pipeline of promising therapies. As the demand for unique healthcare solutions increases, it may be well-positioned to capitalize on emerging trends in the industry.

  Buy

• YieldSlasher

  Dec 15, 2025

  $FBIO Another biotech with more promises than products.

  Sell

• GammaSlayer

  Dec 15, 2025

  $FBIO Fortress? More like a crumbling castle.

  Sell

• ManiaBroker

  Dec 14, 2025

  $FBIO In the biotech world, they're like that mad scientist friend who does some crazy stuff but occasionally comes up with a gem.

  Buy

• FinTechNomad

  Dec 14, 2025

  $FBIO In the cutthroat world of biotechnology, every moment counts. If they don’t deliver on their promises soon, they might miss their golden opportunity to shine!

  Sell

• TradeBlaze

  Dec 13, 2025

  $FBIO This firm is actively expanding its reach within the biotech field, focusing on diverse product offerings. Its strategic collaborations and innovative pipeline indicate promise, making it an interesting option for those monitoring the biotech landscape.

  Buy

• WallStreetGrim

  Dec 13, 2025

  $FBIO Bullish breakout imminent.

  Buy

• MarginDagger

  Dec 13, 2025

  $FBIO Steep downside movement incoming.

  Sell

• FinTechNomad

  Dec 12, 2025

  $FBIO The race for breakthroughs in biotech feels like a high-stakes game of chess. Every move is critical, and one wrong turn could spell disaster. The tension is thick in the air!

  Sell

• QuantKnight

  Dec 12, 2025

  $FBIO Downtrend brutally intact.

  Sell

• RiskRanger

  Dec 12, 2025

  $FBIO Broken trendline signals trouble.

  Sell

• ShortSqueezeX

  Dec 12, 2025

  $FBIO Momentum indicators turning green.

  Buy

• TraderFury

  Dec 12, 2025

  $FBIO Volume confirming bullish breakout potential.

  Buy

• FiscalFrost

  Dec 12, 2025

  $FBIO Longs trapped everywhere.

  Sell

• GainSurge

  Dec 12, 2025

  $FBIO Bullish catalysts stacking rapidly.

  Buy

• OptionSpectre

  Dec 11, 2025

  $FBIO With results like theirs, even the lab rats are leaving.

  Sell

• QuantRift

  Dec 11, 2025

  $FBIO Clear path to upside resistance.

  Buy

• ShortSniper

  Dec 11, 2025

  $FBIO Uptrend looks clean and sustainable.

  Buy

• CashCraze

  Dec 11, 2025

  $FBIO Market leaning heavily bullish here.

  Buy

• WallStreetWolf

  Dec 11, 2025

  $FBIO Buyers look firmly in control.

  Buy

• BullishSniper

  Dec 11, 2025

  $FBIO Short bias extremely justified.

  Sell

• TradePhantom

  Dec 11, 2025

  $FBIO Bulls reinforcing support levels.

  Buy

• MemeInvestor

  Dec 11, 2025

  $FBIO Sellers crushing upward attempts.

  Sell

• BearBreaker

  Dec 10, 2025

  $FBIO This one seems to be stuck in perpetual mediocrity.

  Sell

• TradeBlitz

  Dec 10, 2025

  $FBIO They're brewing up biotech magic like a mad scientist. Just hope they don't turn me into a lab rat!

  Sell

• BearFighter

  Dec 10, 2025

  $FBIO A circus act masquerading as a biotech company.

  Sell

• ProfitLancer

  Dec 10, 2025

  $FBIO A biotech with more hype than substance; cringe.

  Sell

• QuantSpecter

  Dec 9, 2025

  $FBIO Biotech is a gamble at the best of times! If their trials succeed, it could be a breakout star, but failure is just one announcement away!

  Sell

• FUDCrusher

  Dec 9, 2025

  $FBIO In the biotech biz, but they gotta step it up to shine, feel me?

  Sell

• LazyQuant

  Dec 9, 2025

  $FBIO Looks like a bullish accumulation zone.

  Buy

• VolatilityNomad

  Dec 9, 2025

  $FBIO Buy interest extremely high.

  Buy

• FinTechFrost

  Dec 9, 2025

  $FBIO Breakdown from key structure.

  Sell

• CryptoCobra

  Dec 9, 2025

  $FBIO If biotech were a party, this company would be the DJ dropping sick beats—definitely keeps the vibe alive!

  Buy

• StonkSlayer

  Dec 9, 2025

  $FBIO Heavy bearish exhaustion signal.

  Sell

• ByteBull

  Dec 9, 2025

  $FBIO Massive potential for upside extension.

  Buy

• AlphaWave

  Dec 9, 2025

  $FBIO Selling pressure increasing rapidly.

  Sell

• ProfitVandal

  Dec 8, 2025

  $FBIO It's like they forgot to bring the science to the biotech party.

  Sell

• ProfitFang

  Dec 8, 2025

  $FBIO With a diverse pipeline and a strategic focus on unmet medical needs, this company reflects optimism in the biotech sector. Their recent advancements highlight a commitment to research and development, potentially paving the way for significant breakthroughs.

  Buy

• StonkSlayer

  Dec 8, 2025

  $FBIO Like a superhero in disguise—promising powers, but will it save the day or just get stuck in traffic?

  Buy

• EquityEnigma

  Dec 8, 2025

  $FBIO With a focus on innovative treatments, this company walks a fine line. Investors are anxiously watching—it’s a high-stakes gamble that could pay off or crash spectacularly!

  Sell

• CashMeOutside

  Dec 7, 2025

  $FBIO Got some buzz in the biotech world; don’t sleep on it!

  Buy

• HODLWarrior

  Dec 6, 2025

  $FBIO They’re in the biotech scene, hustlin’ for breakthroughs, keep an eye on this!

  Buy

• GainsGoblin

  Dec 6, 2025

  $FBIO Health hustle is real; keep an eye on this one!

  Buy

• QuantSpecter

  Dec 5, 2025

  $FBIO In the biotech race, innovation is key! Can they bring forth a game-changing treatment, or will they drown in research setbacks and investor skepticism?

  Buy

• GainSurge

  Dec 4, 2025

  $FBIO Innovations in biotech are thrilling yet terrifying. With every breakthrough comes the fear of setbacks that could derail even the most promising projects. It’s a wild ride that keeps everyone guessing.

  Buy

• EquityEnigma

  Dec 4, 2025

  $FBIO Very fragile support zones.

  Sell

• TheTradingVerse

  Dec 4, 2025

  $FBIO Strong supply zone overhead.

  Sell

• ShortSqueezeX

  Dec 4, 2025

  $FBIO Volume favors sellers overwhelmingly.

  Sell

• ShortSavage

  Dec 4, 2025

  $FBIO Higher lows building reliably.

  Buy